Men who have had testicular cancer are more likely to develop prostate cancer

February 23, 2015

ALEXANDRIA, Va. - A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6 percent) than among those without a history of testicular cancer (2.8 percent). Men who have had testicular cancer were also more likely to develop intermediate- or high-risk prostate cancers. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

"Men with a history of testicular cancer should talk with their doctor about assessing their risk for prostate cancer, given there may be an increased risk," said senior study author Mohummad Minhaj Siddiqui, MD, an assistant professor of surgery at the University of Maryland School of Medicine and director of urologic robotic surgery at the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, Md. "It is too soon to make any practice recommendations based on this single study, but the findings provide groundwork for further research into the biologic link between the two diseases."

Researchers analyzed Surveillance, Epidemiology, and End Results (SEER) data on 32,435 men with a history of testicular cancer and 147,044 men with a history of melanoma. Melanoma was used as the control group because there is no known association between melanoma and prostate cancer. It is expected that patients with melanoma would have a similar risk for developing prostate cancer as men in the general population. On average, men in both groups developed prostate cancer about 30 years after their first cancer was diagnosed.

The overall incidence of prostate cancer by age 80 was significantly higher among men with a history of testicular cancer compared to the control (12.6 vs. 2.8 percent). The incidence of intermediate- or high-risk prostate cancer was also increased in the testicular cancer group compared to the control group (5.8 percent vs. 1.1 percent). Testicular cancer was associated with a 4.7 times higher risk of developing all prostate cancers and 5.2 times higher risk of developing intermediate- or high-risk disease.

Dr. Siddiqui remarked that it is important to keep in mind that the chance of developing intermediate- or high-risk prostate cancer is low - 95 percent of men with a history of testicular cancer will not get it.
2015 Genitourinary Cancers Symposium News Planning Team:

Charles J. Ryan, MD, American Society of Clinical Oncology (ASCO); Howard M. Sandler, MD, MS, American Society for Radiation Oncology (ASTRO); and Fred M. Saad, MD, FRCS, Society of Urologic Oncology (SUO).


American Society of Clinical Oncology

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to